“In the Wake of Turbulence: Pazdur’s Move Signals Deeper Change at the FDA”

As a thin layer of dawn light glances off the columns of a great bureaucracy, the inner workings of the FDA stir once again. In the hush behind closed doors, leadership shifts: a seasoned hand returns — not to remain at the center, but to guide the agency back to familiar ground. The arc of trust, so delicately drawn, wavers; with it, the hopes of patients, researchers, and the industry alike. Change is coming, painted as stability — yet carrying the weight of uncertainty.

In early November 2025, the FDA appointed Richard Pazdur — long-standing director of its oncology division — as head of its major drug review arm, the Center for Drug Evaluation and Research (CDER). Pazdur, after 26 years at the agency and as founding head of the oncology office, was widely regarded as a regulatory stalwart: known for his experience, steady hand, and a track record of streamlining cancer drug approvals.

But barely weeks into this new role — amid intensifying internal conflict and institutional turbulence — Pazdur submitted notice of his intent to retire “at the end of the month.” In response, the FDA announced it would send him “back to the oncology office,” effectively removing him from the broader drug-approval leadership — even as he remains within the agency until his departure.

This turn feels less like a retreat and more like a symbolic recalibration. For months, the FDA has endured upheaval: staff departures, public scrutiny, and competing visions for the agency’s future. Pazdur’s return to the oncology division — rather than a straightforward continuation at the top — reflects the unease permeating the institution. What had been hailed as a stabilizing appointment now reveals itself as a temporary stopgap.

To many inside and outside the agency, Pazdur’s short-lived stint at CDER is more than personnel shuffle. It signals a challenge to restoring confidence: not only among patients awaiting new therapies, but in drug developers who rely on consistent regulatory guidance. As one of the most respected regulators in oncology, Pazdur had embodied a bridge between innovation and safety. His reassignment — and planned exit — may widen the fissures.

And yet — even as uncertainty looms, there remains a sense of cautious optimism. Pazdur’s career at FDA is long, and his legacy in oncology is substantial. His return to the oncology office until a successor is appointed may safeguard the continuity of ongoing cancer-drug reviews. It may allow the agency to stabilize one of its most critical divisions while it seeks a longer-term leader.

the agency’s next steps — how it fills the leadership vacuum, how it balances speed and scrutiny, how it rebuilds trust — will determine whether this episode becomes a detour or a turning point. And for patients, practitioners, and industry watchers alike, those decisions may have consequences far beyond the walls of the FDA.

AI Image Disclaimer Visuals are created with AI tools and are not real photographs — they serve as conceptual illustrations.

Sources Pink Sheet / Citeline, Reuters, The Guardian, ASCO Post, Drugs.com